Press Release
<< Back
Verastem Appoints Daniel Paterson as Chief Operating Officer
“On behalf of the Board of Directors and the entire management team, we
wholeheartedly congratulate Dan on his promotion to Chief Operating
Officer,” said
"We have made significant progress in recent years, and we look forward to further building on this momentum as we execute our ongoing clinical studies for VS-6063, VS-4718 and VS-5584,” said Mr. Paterson. “Our goal is to demonstrate the clinical utility of our programs, solidify our position at the forefront of cancer stem cell research and deliver new drugs for patients with cancer worldwide."
Mr. Paterson has served as the Company’s Chief Business Officer since
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063, or defactinib, VS-4718 and VS-5584, and the
Company’s FAK and PI3K/mTOR programs generally, the timeline for
clinical development and regulatory approval of the Company’s product
candidates, and the structure of the Company’s planned or pending
clinical trials. The words “anticipate,” “appear,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue,”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Each forward-looking statement is subject to risks
and uncertainties that could cause actual results to differ materially
from those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s product candidates and preliminary or interim data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials, that data may not be available when we
expect it to be, that the Company will be unable to successfully
complete the clinical development of its product candidates, that the
development of the Company’s product candidates will take longer or cost
more than planned, and that the Company’s product candidates will not
receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading
“Risk Factors” in the Company’s Annual Report on Form 10-K for the year
ended
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com